Adverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer
“We are excited to have Thomas join Adverum as he has significant financial, strategy, and business operations experience,” said
“I am honored and thrilled to join the Adverum team. ADVM-022, a unique intravitreally delivered gene therapy for wet AMD, and other assets in the pipeline represent great opportunities to help improve health outcomes for patients,” said
Mr. Leung has over fifteen years of business experience in healthcare, private equity, and investment banking. Mr. Leung was most recently vice president, business operations at Counsyl, a leading women’s health genetic testing company, which was recently acquired by
Mr. Leung earned his M.B.A. from
On the date Mr. Leung commenced his employment with Adverum, the Company granted Mr. Leung a stock option to purchase 450,000 shares of Adverum common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Mr. Leung entering employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on Nasdaq on the grant date, and will vest over four years, subject to his continued service with Adverum.
About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. As a leader in ophthalmic gene therapy, Adverum has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Amy Figueroa, CFA Investor Relations Consultant email@example.com 650-823-2704
Source: Adverum Biotechnologies, Inc.